Taiwan study monitors MS drug fingolimod for side effects

NCT ID NCT04480853

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 adults in Taiwan with relapsing-remitting multiple sclerosis who are starting fingolimod (Gilenya), a daily pill that helps control the disease. Over 12 months, researchers will watch for specific side effects like slow heart rate, vision problems, liver issues, and low white blood cell counts. The goal is to make sure the drug is safe for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fingolimod (a daily pill that helps control multiple sclerosis by reducing immune attacks on the nervous system)
What this could lead to: If successful, this study will confirm that fingolimod is safe for Taiwanese MS patients, supporting its continued use as a treatment option.
What could go wrong: This is a small, observational safety study (30 people) with no control group, so it cannot prove effectiveness. Side effects like slow heart rate and liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site
RECRUITING

Taichung, 407219, Taiwan
Novartis Investigative Site
WITHDRAWN

Tainan, 704302, Taiwan
Novartis Investigative Site
RECRUITING

Taipei, 10002, Taiwan
Novartis Investigative Site
WITHDRAWN

Taipei, 11220, Taiwan
Novartis Investigative Site
WITHDRAWN

Taoyuan, 33305, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.